New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export BMY’s income statement to Excel — free account
Bristol Myers Squibb Company
BMYHealthcare Drug Manufacturers General
Bristol Myers Squibb Company’s revenue for fiscal 2025 (year ended December 2025) was $48.2 billion, roughly unchanged from fiscal 2024.
- Revenue
- +6.93%
- EPS
- −2.78%
- Free cash flow
- −36.0%
- Total debt
- −12.5%
Quarter to September 2026, against a year earlier
59.43
1.09
+1.87%
Follow BMY
Alert me
What it owns vs. what it owes Q3 FY2026, Sep 30, 2026
It owes $30.3B more in debt than it holds in cash and short-term investments. Shareholders’ equity is 26.4% of the balance sheet. What is a balance sheet?
Owns
$59.0BLong-term assets
$17.2BOther short-term assets
$12.6BCash & short-term investments
Funded by
$23.4BShareholders’ equity
$22.5BOther liabilities
$42.9BDebt
Debt is 48.3% of the total; shareholders’ equity 26.4%.
Net debt has held near 34% of assets since Q4 FY25.
Net debt ÷ assets (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Total assets | $90.0B | $86.5B | $87.6B | $88.8B |
| Net debt (debt less cash) | $34.4B | $34.0B | $32.1B | $30.3B |
| Net debt ÷ assets (right axis) | 38.2% | 39.3% | 36.6% | 34.1% |
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
10,673.00 | 10,486.00 | 11,067.00 | 12,581.00 |
Receivables |
11,414.00 | 9,368.00 | 10,553.00 | 10,639.00 | |
Inventory |
2,690.00 | 2,756.00 | 2,737.00 | 2,704.00 | |
Other current assets |
4,613.00 | 4,597.00 | 4,222.00 | 3,844.00 | |
Total current assets |
29,390.00 | 27,208.00 | 28,579.00 | 29,767.00 | |
Property, Plant, Equpment (Net) |
7,543.00 | 7,658.00 | 7,791.00 | 7,971.00 | |
Long-Term Investments |
396.00 | 366.00 | 397.00 | 378.00 | |
Goodwill and Intangible Assets (Total) |
40,857.00 | 39,984.00 | 39,127.00 | 38,671.00 | |
Long Term Assets (Tax, Deferred) |
5,378.00 | 5,176.00 | 5,362.00 | 5,884.00 | |
Long-term assets (Other) |
6,474.00 | 6,082.00 | 6,378.00 | 6,099.00 | |
Total non-current assets |
60,648.00 | 59,266.00 | 59,055.00 | 59,003.00 | |
Total Assets |
90,038.00 | 86,476.00 | 87,634.00 | 88,772.00 | |
Accounts Payable |
3,575.00 | 4,234.00 | 4,158.00 | 4,628.00 | |
Current Part of Debt |
2,261.00 | 2,308.00 | 1,027.00 | 1,028.00 | |
Other current liabilities |
17,581.00 | 12,616.00 | 13,474.00 | 13,098.00 | |
Total current liabilities |
23,417.00 | 19,158.00 | 18,659.00 | 18,753.00 | |
Long Term Debt (Total) |
42,850.00 | 42,152.00 | 42,093.00 | 41,849.00 | |
Long Term Tax Liability (Deferred) |
222.00 | 211.00 | 222.00 | 228.00 | |
Non-current Liabilities (Other) |
5,043.00 | 4,853.00 | 4,341.00 | 4,538.00 | |
Total non-current liabilities |
48,115.00 | 47,216.00 | 46,656.00 | 46,615.00 | |
Total liabilities |
71,533.00 | 66,374.00 | 65,315.00 | 65,368.00 | |
Additional Paid In Capital |
46,387.00 | 46,374.00 | 46,504.00 | 46,674.00 | |
Common Stock (Net) |
292.00 | 292.00 | 292.00 | 292.00 | |
Retained Earnings |
16,896.00 | 18,287.00 | 20,316.00 | 21,190.00 | |
Treasury Stock |
43,579.00 | 43,515.00 | 43,504.00 | 43,471.00 | |
Common Equity (Total) |
18,505.00 | 20,102.00 | 22,318.00 | 23,404.00 | |
Shareholders Equity (Total) |
18,506.00 | 20,102.00 | 22,319.00 | 23,404.00 | |
Shareholders Equity and Liabilities (Total) |
90,038.00 | 86,476.00 | 87,634.00 | 88,772.00 | |
Shares (Common) |
2,036.00 | 2,042.00 | 2,043.00 | 2,044.00 | |
Shares (Preferred) |
0.00 | — | — | — | |
Shareholders Equity (Tangible) |
(22,352.00) | (19,882.00) | (16,808.00) | (15,267.00) | |
Net Debt |
34,438.00 | 33,974.00 | 32,053.00 | 30,296.00 | |
Total Debt |
45,111.00 | 44,460.00 | 43,120.00 | 42,877.00 |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026